Novo Nordisk vows to launch five multi-blockbuster drugs by 2030 as it shifts toward consumer-style products
Novo Nordisk used its London capital markets day to reassure investors that the company will broaden its pipeline and market new medicines more like consumer products than traditional drugs.
The CEO said the firm aims to bring at least five multi‑blockbuster therapies to market by 2030, building on the momentum from its recent obesity treatments.
This strategic push is intended to revive growth and create a portfolio that can be sold at scale, echoing a consumer‑goods approach to drug commercialization.
In related news, Ipsen’s shares dropped after the U.S. FDA approved a generic competitor for its hormone therapy Somatuline, highlighting the regulatory pressures that can affect pharma valuations.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Pharmalittle: We’re reading about Novo plans to expand its pipeline, early Alkermes ADHD data, and more”
read at STAT ↗
comments(0)
5-min edit window · permanent after that